乐观
$1.99
情景价格
$2.705
-0.083 (-3.05%)收盘时
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
Sunshine Biopharma Inc is not a good buy right now due to its significant decline in stock price and ongoing financial losses. The current price is $2.70, which is a staggering 98.94% lower than its year-to-date high, and the company reported a net income loss of -1,564,048 USD in Q2 2026. Additionally, the RSI is at 29.9, indicating that the stock is oversold, but this does not guarantee a price recovery in the near term.
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Sunshine Biopharma Launches Generic Ondansetron in Canada

Sunshine Biopharma Launches Generic Ondansetron in Canada

mRNA Cancer Vaccines Show Promising Market Potential and Growth

Biotech Stocks Show Strong Pre-Market Moves

Sunshine Biopharma Shares Surge 66% After Reverse Split and Drug Approval
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Sunshine Biopharma Inc is not a good buy right now due to its significant decline in stock price and ongoing financial losses. The current price is $2.70, which is a staggering 98.94% lower than its year-to-date high, and the company reported a net income loss of -1,564,048 USD in Q2 2026. Additionally, the RSI is at 29.9, indicating that the stock is oversold, but this does not guarantee a price recovery in the near term.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。